… PFS was calculated as the time from start of erlotinib until the time of discontinuation of
erlotinib. Duration of response was calculated as the time from when measurement criteria were …

… In this study, concurrent use of AS did not affect the efficacy or toxicity of erlotinib and
gefitinib in patients with advanced NSCLC harboring EGFR mutations. It provides data that can …

… may lower the efficacy of erlotinib as AS suppressive medications have the potential to reduce
the absorption of the medication. This potential interaction is not restricted to erlotinib. For …

… or radiotherapy, and were ineligible for other erlotinib trials (14). A … the favourable efficacy
and safety profile of erlotinib in a large … patients who received erlotinib as their first line therapy. …

… The aim of this study was to evaluate the efficacy and safety of Erlotinib in Japanese
patients with previously treated non-small cell lung cancer (NSCLC). Available tumor biopsy …

… Erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is active
in glioblastoma. We evaluated erlotinib efficacy … and/or concomitant use of enzyme-inducing …

… use of erlotinib in daily practice and the various aspects that govern adherence. We hypothesize
that side-effects play an important role in the way patients use erlotinib… use of erlotinib in …

… This analysis was based on 299 patients who received at least one dose of erlotinib. The
best response rates were a 29% partial response and 44% stable disease in 273 patients who …

… Currently there are no trials that directly compare erlotinib with any other second-… use of
docetaxel. From these data the manufacturer concludes that erlotinib has similar clinical efficacy …

… The efficacy of erlotinib in the treatment of advanced NSCLC is well established.[3–5] In
current international,[6] European[7,8] and US[9] treatment guidelines, a platinum-based …